Brief: Newron Pharmaceuticals Provides Update On STARS Clinical Study With Sarizotan For Treatment Of Rett Syndrome
13/06/2018 06:05
June 13 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* PROVIDES UPDATE ON STARS CLINICAL STUDY WITH SARIZOTAN FOR
TREATMENT OF RETT SYNDROME
* TRIAL NOW EXPECTED TO COMPLETE ENROLLMENT IN H2 2018, WITH
DATA
READOUT EXPECTED IN H1 2019
Source text for Eikon: ID:nNDLZcvH5
Further company coverage: NWRN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study